ORIC-944 trial with AR inhibitors in mCRPC: Phase 1b results and RP2Ds

The standard of care for metastatic ALK+ non-small cell #LungCancer includes treatment with ALK inhibitors. Explore the 5-year follow-up of this phase 3 study to learn about long-term safety of an ALK tyrosine kinase inhibitor, including adverse event management, in patients with ALK+ advanced/metastatic non-small cell lung cancer: https://www.pfi.sr/xw9

HPV16-positive head and neck cancer is projected to be the most dominant type of head and neck cancer in the US by the mid 2030s. PDS Biotech is exploring an expedited approval pathway to shorten the time frame to make PDS0101 available to patients. Read more: https://bit.ly/47LF7Sa

New AusPAR for Pluvicto (lutetium (177Lu) vipivotide tetraxetan) is approved for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Read more: https://lnkd.in/gUbt52RK

New AusPAR for Pluvicto (lutetium (177Lu) vipivotide tetraxetan) is approved for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Read more: https://lnkd.in/gUbt52RK

New Reference: Darolutamide for Non-Metastatic Castration Resistant Prostate Cancer In this phase 3 trial, darolutamide significantly prolonged metastasis-free survival in men with nonmetastatic, castration-resistant prostate cancer compared to placebo, reducing the risk of metastasis or death by 59%. Overall survival and progression-free survival were also improved with darolutamide. The incidence of adverse events was similar between the groups. https://lnkd.in/ewTqGTde

Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE

From #ESMO25: Updated data from the phase 3 #EMBARK trial showed that enzalutamide plus leuprolide significantly improved overall survival compared with leuprolide alone in patients with biochemically recurrent prostate cancer. According to presenting author Stephen Freedland, MD, of Cedars-Sinai, these findings reinforce previous metastasis-free survival data from EMBARK, "show[ing] that enzalutamide with ADT is the standard of care for high-risk, biochemically recurrent prostate cancer patients.” For more 🔗 : https://lnkd.in/eT2QkTJ2

A new study evaluated breast cancer risks in RAD51C carriers based on family history and found that risks for breast cancer were higher in those with a family history, but only at later stages. Additional non-genetic risk factors were also important modifiers of risk.  To learn more read the article at: https://lnkd.in/gEzBGEea Reference: O'Brien, et al. JAMA Oncology. 2025. Online ahead of print. PMID: 41066089. #ICARE #InheritedCancerRegistry #InheritedCancer #HereditaryCancer #BreastCancer #Cancer #CancerGenetics #GeneticTesting #RAD51C #CancerRisks #CancerRiskManagement #CancerPrevention #CancerResearch

Gilead’s Trodelvy did not significantly improve progression-free survival in a key late-stage study for common breast cancer, though early data hints at a possible survival benefit. https://lnkd.in/gsAiZGHM

A new study by Thomas Clausen and his team has found that pancreatic cells naturally produce HSAT, and that this production increases in early pancreatic tumours. Testing for this molecule could help us identify pancreatic cancer earlier at stages where it's more treatable, which would go a long way to changing its reputation as one of the world's deadliest cancers. Full study: https://lnkd.in/dUgCCq8r